The goofy management couldn't even get the name change right. Lumara is too close to Luminal, and has the potential for screw-ups and possible resultant litigation (Remember that the drug is used on pregnant women, a class of patients that won't take kindly to screw-ups that could have been avoided by selecting a drug product name that was unique and different from any other drug product)
And you guys say that we have a "new" Greg, and additional seasoned executives? Yet, they make a product name change that was not too smart (Makena to Lumara).... any seasoned marketing/sales or pharma executive would have considered prescribing mix-ups caused by similar name products.
